Uveitis
Uveitis is a complex and potentially sight-threatening inflammatory condition that affects the uveal tract of the eye. At our company, we specialize in uveitis drug and therapy development services, aiming to advance the field and provide innovative solutions for this challenging disease.
Overview of Uveitis
Uveitis is a broad term that encompasses a group of intraocular inflammatory disorders. It can be classified based on the anatomical location of inflammation, including anterior uveitis (iritis), intermediate uveitis (pars planitis), posterior uveitis (choroiditis), and panuveitis. It can occur as an isolated condition or be associated with various systemic diseases, such as autoimmune disorders and infections. Uveitis can present with a wide range of symptoms, including eye redness, pain, blurred vision, floaters, and sensitivity to light.
Fig.1 Immunopathogenic mechanisms of experimental autoimmune uveitis (EAU). (Egwuagu C. E., et al., 2021)
Therapy Discovery and Development for Uveitis
Biologic therapies, including monoclonal antibodies and cytokine inhibitors, have revolutionized the therapeutic of various autoimmune diseases, and their potential in uveitis management is being actively investigated. For example, inhibitors of TNF-alpha, such as adalimumab and infliximab, have shown efficacy in controlling inflammation and preserving visual function in certain forms of uveitis. Cell-based therapies represent another promising avenue in uveitis therapeutics. These therapies involve the use of immune cells, such as regulatory T cells (Tregs) or mesenchymal stem cells (MSCs), to suppress the immune response and promote tissue repair.
Our company is dedicated to advancing uveitis diagnostics and therapy development through cutting-edge research and development services. We have a diverse therapeutic development platform shown below. If you are interested, you can click the link to learn more.
Our Services
Harnessing our vast expertise and deep-rooted experience, our esteemed organization offers a wide-ranging suite of services specifically designed for the development of therapies targeting uveitis. With unwavering dedication, our team of professionals strives to provide exceptional solutions that fully address the complexities of uveitis.
To test the efficacy of potential therapies, we develop robust animal models that mimic the characteristics of human uveitis. Our team has extensive experience in establishing and validating uveitis models in various species, including mice and rats. These models allow us to evaluate the therapeutic potential of novel compounds and study their mechanisms of action. In addition, we also develop in vitro models using human ocular cells to investigate the cellular and molecular processes involved in uveitis pathogenesis and drug response.
EIU Animal Models
Endotoxin-induced uveitis (EIU) is a widely recognized animal model for studying acute anterior segment inflammation. This model involves the induction of uveitis through the subcutaneous or intraperitoneal injection of lipopolysaccharide (LPS), which leads to the infiltration of inflammatory cells into the anterior segment of the eye.
EAAU Animal Models
Experimental autoimmune anterior uveitis (EAAU), also known as experimental melanin-induced uveitis (EMIU), is an important animal model used to study anterior uveitis. This model involves the peripheral administration of proteins bound to melanin granules, inducing an inflammatory response that closely resembles human anterior uveitis.
Our company specializes in the development and optimization of cell-based models. Whether it is the interaction between inflammatory cells and resident ocular cells or the interplay between immune cells and vascular endothelial cells, our co-culture systems provide a platform to elucidate the mechanisms underlying uveitis pathology.
Our expertise in ocular organoid development allows us to generate miniature models of the uvea, retina, and cornea. These three-dimensional structures recapitulate the cellular composition and organization of the respective ocular tissues, providing a platform to study the complex interactions between different cell types during uveitis.
Our expertise lies in the identification and development of novel therapeutic targets, as well as the design and implementation of preclinical studies to evaluate their efficacy and safety. In addition to the extensive array of services and models mentioned earlier, our proficiency extends to tailoring personalized solutions and creating disease models that precisely cater to your specific requirements. We take pride in our ability to adapt and customize our offerings to meet your unique needs. If our comprehensive range of services has captured your attention, we sincerely welcome you to reach out to us without any hesitation.
Reference
- Egwuagu Charles E., Sahar A. Alhakeem, and Evaristus C. Mbanefo. "Uveitis: molecular pathogenesis and emerging therapies." Frontiers in immunology 12 (2021): 623725.